Abstract:The opportunistic yeast Candida albicans is the most common cause of candidiasis. With only four classes of antifungal drugs on the market, resistance is becoming a problem in the treatment of fungal infections, especially in immunocompromised patients. The development of novel antifungal drugs with different modes of action is urgent. In 2016, we developed a groundbreaking new medium-throughput method to distinguish the effects of antibacterial agents. Using small-angle X-ray scattering for biological samples (BioSAXS), it is now possible to screen hundreds of new antibacterial compounds and select those with the highest probability for a novel mode of action. However, yeast (eukaryotic) cells are highly structured compared to bacteria. The fundamental question to answer was if the ultrastructural changes induced by the action of an antifungal drug can be detected even when most structures in the cell stay unchanged. In this exploratory work, BioSAXS was used to measure the ultrastructural changes of C. albicans that were directly or indirectly induced by antifungal compounds. For this, the well-characterized antifungal drug Flucytosine was used. BioSAXS measurements were performed on the synchrotron P12 BioSAXS beamline, EMBL (DESY, Hamburg) on treated and untreated yeast C. albicans. BioSAXS curves were analysed using principal component analysis (PCA). The PCA showed that Flucytosine-treated and untreated yeast were separated. Based on that success further measurements were performed on five antifungal peptides {1. Cecropin A-melittin hybrid [CA (1-7) M (2-9)], KWKLFKKIGAVLKVL; 2. Lasioglossin LL-III, VNWKKILGKIIKVVK; 3. Mastoparan M, INLKAIAALAKKLL; 4. Bmkn2, FIGAIARLLSKIFGKR; and 5. optP7, KRRVRWIIW}. The ultrastructural changes of C. albicans indicate that the peptides may have different modes of action compared to Flucytosine as well as to each other, except for the Cecropin A-melittin hybrid [CA (1-7) M (2-9)] and optP7, showing very similar effects on C. albicans. This very first study demonstrates that BioSAXS shows promise to be used for antifungal drug development. However, this first study has limitations and further experiments are necessary to establish this application.

Cluster Analysis of Yeast Genome-Wide Expression Patterns Obtained by Treating with Different Antifungal Agents

Use of Haploid Model of Candida Albicans to Uncover Mechanism of Action of a Novel Antifungal Agent.

Genome-wide Analysis of the Expression Profile of Saccharomyces cerevisiae in Response to Treatment with the Plant Isoflavone, Wighteone, as a Potential Antifungal Agent

Response of gene expression in Saccharomyces cerevisiae to amphotericin B and nystatin measured by microarrays.

Chemogenomic Profiling of the Fungal Pathogen Candida Albicans

cDNA microarray analysis of differential gene expression and regulation in clinically drug-resistant isolates of Candida albicans from bone marrow transplanted patients

Systematic Analysis of Functionally Related Gene Clusters in the Opportunistic Pathogen, Candida albicans

The separation and identification of clinical deep fungus and the analysis of drug susceptibility results

Can BioSAXS detect ultrastructural changes of antifungal compounds in Candida albicans?-an exploratory study

Chemogenomic profiling: identifying the functional interactions of small molecules in yeast

DNA Microarray Analysis of Fluconazole Resistance in a Laboratory Candida Albicans Strain.

Cluster analysis allowed to identify antifungal drugs that retain efficacy against Candida albicans isolated from patients with inflammatory diseases of the soft tissues of the maxillofacial area

Analysis of antifungal susceptibility in vitro and fungi distribution in clinics

Application of Gene Chip Technique in Studying Drug Resistance Genes in Candida Albicans

Systematic Prediction of Antifungal Drug Synergy by Chemogenomic Screening in Saccharomyces cerevisiae

Genome-wide Profiling Identifies Saccharomyces Cerevisiae Response in PKC-SLT2 Signaling and Glycogen Metabolic Pathways to Antifungal Compound Calcofluor White

Drug induced proteome changes in Candida albicans: comparison of the effect of beta(1,3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole

Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens

Significance of differential expression profiles of ABC transporters in azole susceptibility between Cryptococcus gattii VGI and VGII strains

Genomics-driven Discovery of the Pneumocandin Biosynthetic Gene Cluster in the Fungus Glarea Lozoyensis

Transcriptional Profiles of the Response to Ketoconazole and Amphotericin B in Trichophyton Rubrum